"Hepatitis C, Chronic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS.
| Descriptor ID |
D019698
|
| MeSH Number(s) |
C02.440.440.120 C02.782.350.350.120 C06.552.380.350.120 C06.552.380.705.440.120
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hepatitis C, Chronic".
Below are MeSH descriptors whose meaning is more specific than "Hepatitis C, Chronic".
This graph shows the total number of publications written about "Hepatitis C, Chronic" by people in this website by year, and whether "Hepatitis C, Chronic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 1 | 2 |
| 2003 | 1 | 1 | 2 |
| 2004 | 3 | 0 | 3 |
| 2005 | 3 | 0 | 3 |
| 2006 | 2 | 0 | 2 |
| 2007 | 1 | 0 | 1 |
| 2008 | 3 | 0 | 3 |
| 2009 | 4 | 2 | 6 |
| 2010 | 6 | 0 | 6 |
| 2011 | 4 | 0 | 4 |
| 2012 | 6 | 0 | 6 |
| 2013 | 3 | 1 | 4 |
| 2014 | 4 | 1 | 5 |
| 2015 | 2 | 1 | 3 |
| 2016 | 15 | 0 | 15 |
| 2017 | 179 | 31 | 210 |
| 2018 | 193 | 14 | 207 |
| 2019 | 65 | 5 | 70 |
| 2020 | 6 | 1 | 7 |
| 2021 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Hepatitis C, Chronic" by people in Profiles.
-
Recent advances in the chromatographic determination of the most commonly used anti-hepatitis C drug sofosbuvir and its co-administered drugs in human plasma. Biomed Chromatogr. 2022 Jan; 36(1):e5238.
-
Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 In Vitro. Antimicrob Agents Chemother. 2021 08 17; 65(9):e0268020.
-
Chronic viral hepatitis C micro-elimination program using telemedicine. The Mexican experience. Rev Esp Enferm Dig. 2021 08; 113(8):624-625.
-
Progress and challenges in the comprehensive management of chronic viral hepatitis: Key ways to achieve the elimination. World J Gastroenterol. 2021 Jul 14; 27(26):4004-4017.
-
Global Utilization Trends of Direct Acting Antivirals (DAAs) during the COVID-19 Pandemic: A Time Series Analysis. Viruses. 2021 07 07; 13(7).
-
Liver Impairment and Hematological Changes in Patients with Chronic Hepatitis C and COVID-19: A Retrospective Study after One Year of Pandemic. Medicina (Kaunas). 2021 Jun 10; 57(6).
-
Prognosis of French COVID-19 patients with chronic liver disease: A national retrospective cohort study for 2020. J Hepatol. 2021 10; 75(4):848-855.
-
[Development of antiviral drugs based on inhibitors of the SARS-COV-2 main protease]. Biomed Khim. 2021 May; 67(3):259-267.
-
Hepatitis C virus micro-elimination: Where do we stand? World J Gastroenterol. 2021 Apr 28; 27(16):1728-1737.
-
Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro. Br J Pharmacol. 2021 06; 178(11):2339-2350.